# EmayGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emaygene

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Jan 7, 2022)
- Investors on record: 1

## About

Established in 2021 and based in Shanghai, China, Shanghai Weimei Gene Technology operates as a gene therapy drug developer that provides gene therapy and drug. The company was incubated by the iHuman Institute of ShanghaiTech University. In June 2023, it raised strategic investment from new investors GP Capital and Hongsheng Capital.

The company provides gene therapy and drug for patients with hearing diseases. The business of the company includes development, production and clinical application of gene therapy drugs. it focuses on cell function and adeno-associated virus. The company's products include AAV-inner ear (AAV-ie).

The company will put the funding towards AAV carrier development, pipeline propulsion, the core team construction.

## Funding rounds

- Angel, Jan 7, 2022 — Laurel Venture

## Investors

- Laurel Venture (https://capitalatlas.ai/funds/laurel-venture) — Angel